Aurinia Pharmaceuticals Inc. (AUPH) stock
AUPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 13/3058% below fair value
$15.13−0.27 (-1.75%)
Close on Nov 18, 2026Market cap $2.03BP/E 6.6Yield –
Aurinia Pharmaceuticals revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Aurinia Pharmaceuticals's revenue for the twelve months ending Sep 30, 2026 was $321.74M, up 21.0% year over year. For fiscal 2025 it was $283.06M, up 20.4% from the year before. The highest annual figure on record is $283.06M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $283.06M | +20.4% |
| FY2024 | Dec 31, 2024 | $235.13M | +34.0% |
| FY2023 | Dec 31, 2023 | $175.51M | +31.0% |
| FY2022 | Dec 31, 2022 | $134.03M | +193.9% |
| FY2021 | Dec 31, 2021 | $45.61M | -9.0% |
| FY2020 | Dec 31, 2020 | $50.12M | +15660.4% |
| FY2019 | Dec 31, 2019 | $318.00K | -31.3% |
| FY2018 | Dec 31, 2018 | $463.00K | +10.8% |
| FY2017 | Dec 31, 2017 | $418.00K | +141.6% |
| FY2016 | Dec 31, 2016 | $173.00K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $83.70M | +13.9% |
| Q2 FY2026 | Jun 30, 2026 | $83.22M | +18.9% |
| Q1 FY2026 | Mar 31, 2026 | $77.71M | +24.4% |
| Q4 FY2025 | Dec 31, 2025 | $77.11M | +28.8% |
| Q3 FY2025 | Sep 30, 2025 | $73.47M | +8.4% |
| Q2 FY2025 | Jun 30, 2025 | $70.01M | +22.4% |
| Q1 FY2025 | Mar 31, 2025 | $62.47M | +24.2% |
| Q4 FY2024 | Dec 31, 2024 | $59.87M | +32.8% |
| Q3 FY2024 | Sep 30, 2024 | $67.77M | +24.3% |
| Q2 FY2024 | Jun 30, 2024 | $57.19M | +37.8% |
| Q1 FY2024 | Mar 31, 2024 | $50.30M | +46.2% |
| Q4 FY2023 | Dec 31, 2023 | $45.10M | +58.6% |
| Q3 FY2023 | Sep 30, 2023 | $54.52M | -2.3% |
| Q2 FY2023 | Jun 30, 2023 | $41.49M | +47.2% |
| Q1 FY2023 | Mar 31, 2023 | $34.41M | +59.1% |
| Q4 FY2022 | Dec 31, 2022 | $28.44M | +21.5% |
| Q3 FY2022 | Sep 30, 2022 | $55.78M | +280.3% |
| Q2 FY2022 | Jun 30, 2022 | $28.19M | +325.8% |
| Q1 FY2022 | Mar 31, 2022 | $21.63M | +2266.0% |
| Q4 FY2021 | Dec 31, 2021 | $23.40M | -53.2% |
| Q3 FY2021 | Sep 30, 2021 | $14.67M | +50475.9% |
| Q2 FY2021 | Jun 30, 2021 | $6.62M | +22727.6% |
| Q1 FY2021 | Mar 31, 2021 | $914.00K | +2946.7% |
| Q4 FY2020 | Dec 31, 2020 | $50.03M | +172417.2% |
| Q3 FY2020 | Sep 30, 2020 | $29.00K | -87.4% |
| Q2 FY2020 | Jun 30, 2020 | $29.00K | 0.0% |
| Q1 FY2020 | Mar 31, 2020 | $30.00K | 0.0% |
| Q4 FY2019 | Dec 31, 2019 | $29.00K | – |
| Q3 FY2019 | Sep 30, 2019 | $230.00K | – |
| Q2 FY2019 | Jun 30, 2019 | $29.00K | – |
| Q1 FY2019 | Mar 31, 2019 | $30.00K | – |
See a number that looks wrong?